Skip to main content
Premium Trial:

Request an Annual Quote

Cepheid Inks $15M Credit Line

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Cepheid said that it has entered into a loan and security agreement with Silicon Valley Bank, providing the firm with a revolving credit line of up to $15 million.

The credit line has a maturity date of June 7, 2012 and bears an interest rate "equal to SVB's most recently announced prime rate … but in no case less than" 4 percent, the firm said in a filing this week with the US Securities and Exchange Commission.

In addition, the agreement includes a total term line of $6 million — $2 million of which was made effective on the date of the loan agreement; $2 million that must be requested by Cepheid no later than Aug. 1, 2010; and $2 million that Cepheid must request no later than Nov. 1, 2010. The maturity date for each term loan is 48 months following the loan.

The Scan

WHO Seeks Booster Pause

According to CNN, the World Health Organization is calling for a moratorium on administering SARS-CoV-2 vaccine boosters until more of the world has received initial doses.

For Those Long Legs

With its genome sequence and subsequent RNAi analyses, researchers have examined the genes that give long legs to daddy longlegs, New Scientist says.

September Plans

The New York Times reports that the US Food and Drug Administration is aiming for early September for full approval of the Pfizer-BioNTech SARS-CoV-2 vaccine.

Nucleic Acids Research Papers on Targeting DNA Damage Response, TSMiner, VarSAn

In Nucleic Acids Research this week: genetic changes affecting DNA damage response inhibitor response, "time-series miner" approach, and more.